sanofi-aventis sales and marketing update

sanofi-aventis launched I.V. Jevtana cabazitaxel in the U.S. to treat metastatic hormone-refractory prostate cancer (mHRPC) in patients previously treated with a docetaxel-based regimen. A 25 mg/m 2 ...